Estimating the Real Option Value of Osimertinib Compared to Standard EGFR-TKI in the Treatment of Advanced NSCLC in the United States. - Adjei K; Diaby V; Li M; Sherbeny F; Suther S; Ali AA (Clinical drug investigation, 2026)